Engflag

Mebeverine

Quick links to important sections

Mebeverine

Mebeverine_FR

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Mebeverine

What is Mebeverine?

Mebeverine is a type of medication known as an antispasmodic. It is primarily used to manage symptoms associated with functional bowel disorders, most notably irritable bowel syndrome (IBS) and similar conditions characterized by muscular spasms in the gastrointestinal tract.

Mechanism of Action

Unlike some other medications used for digestive issues, mebeverine works directly on the smooth muscles of the gut. It acts as a selective relaxant, helping to relieve cramps and spasms without significantly affecting the normal movement (motility) of the intestines. By targeting the smooth muscle cells, it helps to reduce pain and discomfort associated with overactivity of the digestive system.

Therapeutic Use

Mebeverine is typically utilized to address a range of symptoms, including:

  • Abdominal pain and cramps
  • Persistent diarrhea (especially when alternating with constipation)
  • Flatulence and bloating
  • Small-volume, hard, or pellet-like stools

Because it does not belong to the class of medications known as anticholinergics, it is often considered for patients who may be sensitive to the side effects associated with those drugs. It is available in various formulations, including immediate-release tablets and sustained-release capsules, designed to provide consistent symptom relief throughout the digestive process.

Regulatory References

  1. Mebeverine Public Assessment Report

What side effects are possible with Mebeverine?

Possible side effects and safety information

Mebeverine's officially documented safety profile centers predominantly on hypersensitivity reactions, or allergic responses, reported through post-marketing surveillance. This type of voluntary reporting system limits the ability to precisely determine the frequency of occurrence for most documented events, resulting in the official classification of most adverse reactions as Frequency Not Known.

Adverse Reactions by System-Organ Class

The most commonly noted adverse reactions are grouped within the Immune system disorders and Skin and subcutaneous tissue disorders categories. These include non-serious reactions such as urticaria (hives), rash, and pruritus (itching).

Serious Adverse Reactions

Official regulatory documents list more severe manifestations of hypersensitivity as serious adverse reactions. These include Angioedema (swelling of the face, lips, tongue, or throat), Face Oedema, and systemic Anaphylactic reactions.

Population-Specific Safety Constraints

Official regulatory guidance imposes specific safety constraints for certain populations, primarily due to insufficient data on efficacy and safety in these groups:

  • Paediatric Population: Not recommended for use in children and adolescents under 18 years of age.
  • Pregnancy and Breast-feeding: Use is generally not recommended during pregnancy or while breast-feeding.

Mebeverine is also contraindicated in individuals with a known allergy to the active ingredient or its components, as well as in patients with certain pre-existing conditions like paralytic ileus. Additionally, the presence of excipients such as lactose may restrict its use in patients with specific hereditary intolerances.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for mebeverine overdose strictly requires immediate medical attention. If an overdose is suspected, the patient must seek immediate medical attention and is instructed to talk to a doctor or go to a hospital straight away, as stated in governmental patient and prescribing information.

Documented Overdose Manifestations

The documented clinical experience in cases of mebeverine overdose shows that symptoms are typically absent or mild, and generally rapidly reversible. Observed clinical effects have been reported to be of a neurological nature and a cardiovascular nature, with Central Nervous System (CNS) excitability listed as a theoretical possibility. These observations define the extent of the documented manifestations.

Official Management Protocol

Management is restricted to providing symptomatic treatment because the regulatory labeling confirms that no specific antidote is known. Intervention procedures are clearly constrained: Gastric lavage should only be considered under limited circumstances, specifically in cases of multiple intoxication or if ingestion is discovered within approximately one hour. Furthermore, the official guidelines state that absorption reducing measures are not necessary. Regulatory data on special populations, such as the elderly or those with hepatic or renal impairment, have not identified a specific differential overdose risk.

Therapeutic Uses of Mebeverine

Quick Facts: Therapeutic Areas

  • Irritable Bowel Syndrome (IBS): May assist in the management of symptoms associated with this condition.
  • Abdominal Discomfort: Used for the relief of colicky pain and cramps in the gastrointestinal region.
  • Functional Bowel Disorders: May contribute to the management of symptoms linked to other intestinal functional disturbances.

Mebeverine is a medication utilized for the symptomatic management of conditions involving intestinal smooth muscle spasms. The primary therapeutic use is to provide relief for symptoms associated with Irritable Bowel Syndrome (IBS). These symptoms typically include abdominal pain, cramps, and other instances of discomfort and spasm in the digestive tract.

It may also be considered in the context of other functional bowel disturbances, which can manifest as chronic irritable colon, spastic constipation, or certain types of colitis. The administration of this agent is intended to contribute to the reduction of painful episodes and discomfort, which may include symptoms such as non-specific diarrhea (potentially alternating with constipation) and flatulence.

Patients should consult with a healthcare professional to confirm its appropriateness for their specific symptom profile.

Regulatory References

  1. NIH MedlinePlus Mebeverine guidance

Eligibility and Restrictions for Use

The eligibility for using Mebeverine is strictly defined by regulatory documents, distinguishing between approved, restricted, and contraindicated populations. The medicine is primarily established for use in Adults, including the elderly.

Contraindications and Restrictions

Category Official Regulatory Status
Populations for whom use is allowed (as stated in label) Adults (including the elderly).
Populations for whom use is not recommended Children and adolescents below 18 years due to insufficient data on safety and efficacy; Pregnant women (limited data); Breastfeeding mothers (use should not be adopted).
Populations for whom use is contraindicated Patients with known hypersensitivity to the active substance or excipients; Patients with rare hereditary sugar intolerances (e.g., galactose intolerance, total lactase deficiency) due to lactose content.

Age and Organ Status

Use in the pediatric population (below 18 years) is officially not recommended for standard capsule and tablet formulations, and is contraindicated for use in children below three years. For patients with hepatic impairment or renal impairment, regulatory documents note that while no dosage adjustment is deemed necessary, no posology studies have been performed in these specific groups. The constraints are formally defined by regulatory agencies based on available clinical evidence.

What should I know about interactions with other medicines?

Interaction Map: Interactions with other medicines and products — official regulatory information for Mebeverine

Interaction Scope

Category Official Regulatory Statement
Medicinal product categories with documented interactions None explicitly defined, as the drug is not known to interact with other medicines.
Specific interacting medicines (if explicitly listed) None explicitly listed as having a formal interaction.
Mechanistic basis of interactions (only if stated in label) No interaction mechanisms (e.g., CYP-inhibition, transporter effects) are officially stated in relation to co-administered drugs.
Timing-based interaction rules (if applicable) None officially stated for co-administered medicines.
Population-specific interaction notes (if applicable) None officially stated regarding increased interaction severity in specific populations.
Interaction-related restrictions No formal 'do-not-combine' rules or regulatory restrictions are documented based on interaction studies.

Interaction Classifications (High-Level)

Classification Official Regulatory Statement
Interaction severity classification (as defined in official documents) Not classified, due to the officially documented absence of known interactions with other medicines.
Regulatory basis Based on national and regional governmental drug agency prescribing information (e.g., EMA/HPRA SmPC).
Interaction-context constraints (as defined in official documents) No specific constraints are documented because no clinically relevant or formal interactions with other medicines are specified.

Resulting Interaction Structure

Official interaction statements:

  • Mebeverine is officially stated to be not known to interact with other medicines.
  • No formal drug-drug interaction studies have been performed beyond an examination of alcohol.
  • Official regulatory review confirms that no interaction has been demonstrated between mebeverine and ethanol (alcohol).

Connection to the overall interaction profile (2–4 sentences): Official regulatory documentation defines mebeverine's interaction structure by explicitly stating the drug's lack of known interactions with other medicinal products. This results in the absence of formal contraindicated combinations, mandatory administration timing rules, or documented metabolic or transporter-mediated interaction effects in the labeling. The official data for alcohol confirms no interaction with ethanol, establishing a minimal interaction profile for the substance.

Mechanism of Action

Mechanism of Action: How Mebeverine Works

Mebeverine primarily acts as a musculotropic antispasmodic agent with a high affinity for the smooth muscle of the gastrointestinal (GI) tract. Its core mechanism involves modulating the movement of calcium ions ( Ca^2+) across cell membranes. Specifically, mebeverine inhibits voltage-gated Ca^2+ channels in the smooth muscle cells, reducing the intracellular concentration of the ion required to activate the contractile apparatus. This modification of the early molecular steps within the smooth muscle cascade alters the threshold for cellular depolarization and contraction.

Additionally, mebeverine demonstrates a localized neural effect by modulating sodium ion ( Na^+) channels and noradrenaline reuptake near the myenteric plexus. These actions decrease afferent neural signaling and intrinsic membrane excitability in the muscle cells. The combined effect on ion channels and neural regulation results in an altered electromechanical coupling and reduced baseline muscle tone, contributing to a controlled modulation of GI smooth muscle activity.

Dosage and Administration Information

Official Administration Guidelines

Mebeverine is indicated for oral administration across its standard formulations, including 135 mg film-coated tablets and 200 mg modified-release capsules. The administration protocol is determined by the dosage form being used.

Labeled Dosing and Scheduling

Feature Guideline (Adults, Including Elderly)
Standard Tablets (135 mg) One tablet three times a day.
Modified-Release Capsules (200 mg) One capsule twice a day (morning and evening).
Maximum Daily Dose 405 mg (three 135 mg tablets) or 400 mg (two 200 mg capsules).

Administration Instructions and Constraints

The medicine should be taken before meals, with standard instructions specifying a time relationship of approximately 20 minutes prior to eating. Tablets and capsules must be swallowed whole with a sufficient amount of water (e.g., at least 100 mL). It is a procedural instruction that modified-release capsules must not be chewed or opened, as this action compromises the mechanism intended to provide prolonged release of the active ingredient. Tablets should also not be chewed due to their unpleasant taste.

Special Populations and Duration

No dosage adjustment is deemed necessary for older adults, or for patients with renal or hepatic impairment. However, the medicine is not recommended for use in children and adolescents below 18 years, due to insufficient data on safety and efficacy. The duration of use is generally not limited in standard clinical practice, allowing for use to be stopped once symptoms have subsided. If a dose is missed, patients should continue with the next scheduled dose; the missed dose must not be taken in addition to the regular dose.

Recent Clinical Evidence

Evidence for Use in Irritable Bowel Syndrome (IBS) and Functional Bowel Disorders

The core research on this medicine involves studies exploring its use for Irritable Bowel Syndrome (IBS) and other functional bowel disorders. These are conditions characterized by fluctuating or episodic manifestations. The evidence base includes multiple Randomized Controlled Trials (RCTs) and Systematic Reviews and Meta-analyses. Researchers in these studies examined patient-reported outcomes describing perceived discomfort, focusing on the assessment of symptom success, adequate relief, and changes in the intensity of abdominal pain, cramping, and abnormal bowel habits. Studies contribute to the broader evidence landscape by providing insight into short-term changes in these patterns.

Study Design and Assessment of Symptom Relief

The research explored short-term symptom changes, with most core studies involving observation periods of 4 to 12 weeks. Findings were mixed across studies; older meta-analyses often reported that aggregated data did not show a statistically significant difference in global symptom improvement when compared directly to the placebo group. However, more recent reviews have contained data focusing on abdominal pain, where research describes observed patterns related to short-term changes in intensity and frequency. The evidence structure is varied across studies, leading to complexity in drawing universal conclusions.

Long-Term Evidence and Durability of Response

The follow-up durations for the pivotal clinical trials were limited, meaning the current research primarily offers insight into short-term changes only. Long-term effects are not fully established. Studies that track the use of this medicine for long periods are typically observational studies, where patients are monitored in daily-life settings, rather than controlled RCTs. Therefore, prospective data for long-term outcomes and the durability of any measured effect remain insufficient from controlled trials.

Evidence in Special Populations

The research applies mainly to adults, but some studies have explored its use in adolescents (aged 12 to 18 years) with IBS symptoms. For this adolescent population, data are still emerging and remain insufficient for a definitive assessment. Research focusing on these young patients reported results that were not consistently distinguishable from what was observed in the placebo group.

Review of Evidence Quality and Uncertainty

The current scientific understanding of this medicine reflects a body of evidence that has led to inconsistent and conflicting interpretations of measured clinical outcomes according to specialized reviews. The evidence structure is varied across studies due to methodological differences. One recognized challenge is the influence of patient expectation, sometimes referred to as a labeling effect, which is observed to complicate how perceived discomfort is reported in some blinded trials. Certainty remains low in areas where data for specific groups remain insufficient.

Key Studies & References

  1. The Efficacy of Mebeverine in the Treatment of Irritable Bowel Syndrome—A Systematic Review
  2. Rome IV Criteria (for Functional Gastrointestinal Disorders and Irritable Bowel Syndrome)
  3. Public Assessment Report Scientific discussion Mebeverine Aristo 200 mg modified release capsules, hard (Regulatory Assessment)

Frequently Asked Questions (FAQ)

Common questions about Mebeverine (FAQ)

Q: Can Mebeverine be used for general, non-IBS related stomach cramps or aches?

Official product labeling indicates that Mebeverine is intended for the symptomatic treatment of intestinal spasm and discomfort associated specifically with Irritable Bowel Syndrome (IBS) or other functional bowel disorders. This means its approved use is focused on treating spasms related to these specific gastrointestinal conditions.

Q: How long do the effects of Mebeverine typically last?

The intended duration of the effect is reflected in the official dosing schedule for the modified-release capsule, which is generally structured for administration twice per day. This frequency is designed to sustain the medicine’s action throughout a 24-hour period.

Q: Can Mebeverine make a person feel tired or drowsy?

The official adverse event profile for this medicine does not commonly list tiredness or drowsiness as reported side effects. However, potential side effects are classified according to reports from surveillance, and not all events are listed by frequency.

Q: Does Mebeverine affect a person's ability to drive?

Official regulatory guidance states that Mebeverine has no or negligible influence on the ability to drive or operate machinery. However, regulatory documents indicate that if a person experiences dizziness—a reported reaction—their ability to drive or use machines may be affected.

Q: Does Mebeverine contain gluten or lactose?

Official regulatory documents confirm the presence of lactose as an excipient in some Mebeverine formulations. This ingredient is noted as a restriction for people with certain hereditary sugar intolerances. Gluten content is generally not noted as a restriction.

Q: Can people with high blood sugar use Mebeverine?

The official regulatory contraindications for Mebeverine do not list high blood sugar (diabetes) or related metabolic conditions as a factor that precludes its use. Contraindications are limited to conditions such as known hypersensitivity, paralytic ileus, and certain hereditary sugar intolerances.

Q: Does Mebeverine help specifically with bloating?

The medicine is officially indicated for the relief of general abdominal discomfort associated with Irritable Bowel Syndrome. Relief of symptoms may include effects on cramping, pain, and associated bloating.

Q: Is Mebeverine effective for individuals who experience constipation-dominant IBS?

Clinical evidence for Mebeverine examines the overall relief of abdominal pain and discomfort across different types of Irritable Bowel Syndrome. The regulatory information generally applies to IBS symptoms, which includes those experienced by individuals with the constipation-dominant subtype.

Q: Do studies show Mebeverine is effective for long-term IBS management?

The official labeling indicates that the duration of use for Mebeverine is generally not limited, and regulatory guidance allows use to be discontinued once symptoms have subsided, supporting its use on an as-needed basis for managing recurring symptoms.

Q: Is Mebeverine considered a cure for Irritable Bowel Syndrome (IBS)?

No. Official regulatory documents indicate that the drug is approved for the symptomatic treatment of IBS. This means Mebeverine is intended to relieve the discomfort and spasms associated with the condition, rather than providing a cure for the underlying cause.

Q: Can Mebeverine cause dizziness or affect balance?

Dizziness is listed in official documents as a reported adverse reaction. However, the exact frequency of this occurrence is typically categorized as 'Frequency Not Known' based on regulatory surveillance data.

Q: Is it common to experience skin reactions or itching with Mebeverine?

Skin reactions, such as rash and itching (pruritus), are listed as potential adverse reactions. However, because this data relies on post-marketing surveillance, the official frequency is classified as 'Frequency Not Known,' meaning it cannot be definitively described as 'common.'

Q: Can Mebeverine be taken safely alongside prescribed antibiotics?

Official product labeling states that Mebeverine is not known to interact with other medicinal products. This broad statement covers common drug classes, including antibiotics.

Q: Does Mebeverine interact with common over-the-counter pain relievers?

According to the official product information, Mebeverine is not known to interact with other medicinal products. This broad coverage applies to common over-the-counter pain relievers.

Q: Are there different strengths of Mebeverine available?

Regulatory documents list the two standard approved strengths: the 135 mg film-coated tablets and the 200 mg modified-release capsules. These are the formulations available for oral administration.

Q: Is Mebeverine considered a strong painkiller?

No. Mebeverine is officially classified as a musculotropic antispasmodic agent. It is intended for the symptomatic relief of muscle spasms in the gut and is not classified as an analgesic or strong painkiller.

Q: Is Mebeverine officially recommended for use with other IBS medicines?

The official documents do not list known interactions with other medicines, which means co-administration is not restricted. However, there is no formal recommendation for combination therapy within the single-product label.

Q: Is Mebeverine used to treat pain from gallstones?

The official regulatory indication for Mebeverine is strictly the symptomatic treatment of Irritable Bowel Syndrome and functional bowel disorders. It is not indicated for the treatment of pain related to gallstones or biliary colic.

Q: Is Mebeverine approved for use in children under 12?

The official guidance states that Mebeverine is not recommended for use in children and adolescents below 18 years of age. This restriction is due to insufficient regulatory data on efficacy and safety within this younger age group.

Q: Are there specific dietary restrictions to follow while using Mebeverine?

The regulatory documents do not list any specific food or dietary restrictions. The official interaction section addresses medicinal products and alcohol, but does not impose restrictions on general diet.

Q: Is Mebeverine a prescription-only medicine? (Classification)

The regulatory classification of Mebeverine varies by region and governing authority. In some areas, it may be classified as a Prescription Only Medicine (POM), while in others, it may be available as a Pharmacy Medicine (P).

Q: Can Mebeverine be taken with food? (Factual instruction, non-directive)

Official administration instructions specify that the medicine should be taken before meals for the optimal therapeutic effect. Following this timing is noted in the regulatory documents.

How should Mebeverine be stored and disposed of?

How to Store and Dispose of Mebeverine?

Mebeverine must be stored under specific environmental constraints to maintain its stability. The official regulatory documents require the medicine to be stored at a temperature not greater than 30°C and in a dry place.

Protection from light is a mandatory storage condition. Critically, mebeverine must be kept out of the sight and reach of children.

For disposal, do not throw away unused or expired medicine via wastewater or household waste. Instead, individuals are advised to follow official local regulations or ask a pharmacist for guidance on disposal, with drug take-back programs being a widely preferred method.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Mebeverine found in:

A-Z Index: